PARIS (Agefi-Dow Jones) – Ipsos on Monday waived the appointment of Nathalie Roos as chief executive, which was due to take effect this week, and announced that it would ultimately be the head of its UK subsidiary, Ben Page, 56, who would lead the group.
Already a member of the executive committee, Ben Page has been Managing Director of Ipsos MORI in the UK since 2009. He is scheduled to take up his new post on November 15. The founder and current boss of the group, Didier Truchot, will retain the chairmanship of the board of directors.
“Ipsos and Nathalie Roos have decided by mutual agreement to discontinue their project at the end of which Nathalie Roos was to take up the duties of general manager of Ipsos soon,” said the study group by inquiries in a press release. This decision was taken because of “deep differences” appeared during “in-depth discussions” between the person concerned and Didier Truchot, said Ipsos, without providing further explanation.
General Manager of the L’Oréal group’s professional products division until last March, Nathalie Roos was selected last July to take the reins of the polls and market research group from September 28.
This last-minute turnaround “does not call into question Ipsos’ plans to pursue the execution of its development plan materialized by the implementation of the strategic initiative called ‘Total Understanding Project’ in July 2018 and the consequence of which the most visible has been a return to stronger business growth, “Ipsos said.
Ipsos cancels the appointment of its new boss on the eve of taking office | Dow jones
Ipsos Acquires New Zealand Infotools in Market Research Data Analysis and Processing | invest.fr
PASSAT: It’s confirmed, Passat will suffer from rising costs
PISCINES DESJOYAUX: The attraction of the individual swimming pool cannot be denied
ICADE SANTE: The biggest fundraising of the year on Euronext Paris with Icade Santé
ILIAD: Xavier Niel’s takeover closed on Friday
CABASSE GROUP: The best at Cabasse Group
Order book quadruples for pleasure boat manufacturer Catana
Sanofi will not develop a Phase III clinical trial for its COVID-19 mRNA vaccine